Gajanan Sapkal - Concepedia

Author

Gajanan Sapkal

ICMR-National Institute of Virology ORCID

Also Known As

G N Sapkal, G. N. SAPKAL, G. N. Sapkal, G. Sapkal, G.N. Sapkal, Gajanan N Sapkal, Gajanan N. Sapkal, Gajanan Sapkal, Pragya Yadav

162

Publications

5.2K

Citations

H-Index

Concepts

All Affiliations

ICMR-National Institute of Virology Indian Council of Medical Research Bharat Biotech (India)Armed Forces Medical College All India Institute of Medical Sciences

About

Gajanan Sapkal is an author at ICMR-National Institute of Virology specializing in medicine, virology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	23	41	2.2K
2	Immunology	21	35	2K
3	Epidemiology	12	12	440
4	Public Health	4	4	85
5	Allergy	2	2	27

Gajanan Sapkal

Publications

3.9K

Citations

H-Index

Page 1

	Year	Citations
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial Raches Ella, Krishna Mohan Vadrevu, Harsh Jogdand, The Lancet Infectious Diseases VaccinationVaccine SafetyVaccine DevelopmentImmunologyVirology	2021	433
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial Raches Ella, Siddharth Reddy, Harsh Jogdand, The Lancet Infectious Diseases	2021	360
Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial Raches Ella, Siddarth Reddy, William C. Blackwelder, The Lancet VaccinationVaccine SafetyVaccine DevelopmentImmunologyInterim Results	2021	358
Burden of dengue infection in India, 2017: a cross-sectional population based serosurvey Manoj Murhekar, P Kamaraj, Muthusamy Santhosh Kumar, The Lancet Global Health	2019	143
Neutralization of variant under investigation B.1.617 with sera of BBV152 vaccinees Pragya D. Yadav, Gajanan Sapkal, Priya Abraham, Investigation B.1.617Viral DiagnosticsImmunologyCovid-19Emerging Infectious Disease	2021	137
Inactivated COVID-19 vaccine BBV152/COVAXIN effectively neutralizes recently emerged B.1.1.7 variant of SARS-CoV-2 Gajanan Sapkal, Pragya D. Yadav, Raches Ella, Journal of Travel Medicine VaccinationB.1.1.7 VariantVaccine DevelopmentImmunologyVirology	2021	128
Enteroviruses in Patients with Acute Encephalitis, Uttar Pradesh, India Gajanan Sapkal, Vijay P. Bondre, Pooja R. Patil Emerging infectious diseases	2009	114
Neutralization of Beta and Delta variant with sera of COVID-19 recovered cases and vaccinees of inactivated COVID-19 vaccine BBV152/Covaxin Pragya D. Yadav, Gajanan Sapkal, Raches Ella, Journal of Travel Medicine VaccinationSars-cov-2 VariantVaccine DevelopmentDelta VariantsVaccine Target	2021	113
Th1 skewed immune response of whole virion inactivated SARS CoV 2 vaccine and its safety evaluation Brunda Ganneru, Harsh Jogdand, Vijaya Kumar Daram, iScience	2021	92
Immunogenicity and protective efficacy of inactivated SARS-CoV-2 vaccine candidate, BBV152 in rhesus macaques Pragya D. Yadav, Raches Ella, Sanjay Kumar, Nature Communications	2021	87

Page 1